Physicians' Academy for Cardiovascular Education
Grand Debate on Sacubitril/Valsartan: is it ready to be used as first-line therapy?

Grand Debate on Sacubitril/Valsartan: is it ready to be used as first-line therapy?

News - May 1, 2017

Paris, France | The Grand Debate 1: Neprilysin inhibitor - Vasodilators: LCZ 696 (Sacubitril/Valsartan)

Disclosures

Our coverage of ESC HF 2017 is based on the information provided during the congress.

Share this page with your colleagues and friends: